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Summary The growth rate of the MAC16 tumour in cachectic animals was significantly enhanced by the
hypolipidemic agent bezafibrate, while the growth rate of a histologically similar tumour, the MAC13, which
grows without an effect on host body compartments was unaffected. Growth of the MAC16 in vitro was
unaffected by bezafibrate, suggesting that it was an in vivo phenomenon only. The stimulatory effect of
bezafibrate correlated with the maximum plasma levels offree fatty acids (FFA) arising from the catabolism of
adipose tissue. Accumulation of '4C-lipid from 1-'4C-triolein administered by intragastric intubation was
enhanced in heart, gastrocnemius muscle and tumour of bezafibrate treated animals, while the total lipid
absorption did not differ from solvent treated controls. The increased lipid accumulation in the heart, but not
the tumour correlated with an increased tissue lipoprotein lipase level. The increased tumour level may arise
from an increased uptake of FFA arising from a weakening of the bonds between FFA and albumin. These
results suggest that growth of certain tumours is dependent on maintaining sufficient lipid levels and that the
lipid mobilising effect of the tumour may be necessary to sustain tumour growth.
Although tumour cells retain the metabolic capacity for the
synthesis of fatty acids (Medes et al., 1953; Mulligan &
Tisdale, 1991) the flux through this pathway may be
insufficient to meet the tumour's needs and a substantial
amount is obtained preformed from the host (Spector, 1975).
The host responds to the tumour by releasing increased
amounts of lipid into the circulation and either the cir-
culatory free fatty acids (FFA) (Mermier & Baker, 1974), or
to a lesser extent triglycerides contained in plasma lipo-
proteins, are available for the tumour (Lyon et al., 1982). A
number of experimental tumours have a high relative in vivo
uptake of low density lipoprotein (LDL) (Lombardi et al.,
1989). In some cases this results in frank hyperlipidemia
(Mider et al., 1949), but if the lipid requirements of the
tumour/host are high, then plasma FFA and triglyceride may
be decreased despite an enhanced lipid mobilisation (Briddon
et al., 1991).
Increases in the mobilisation of host fat stores either by an
acute fast (Sauer & Dauchy, 1987a) or by acute
strepozotocin-induced diabetes (Sauer & Dauchy, 1987b) lead
to an increased tumour growth as measured by an increased
size and by incorporation of (methyl-3H)thymidine into
tumour DNA. These results indicate that the rate of tumour
growth in vivo is limited by the availability of a substance(s)
present in the hyperlipemic blood, most probably the polyun-
saturated fatty acids linoleic and arachidonic acid (Sauer &
Dauchy, 1988). This suggests that it may be possible to
modulate tumour growth in vivo by altering the supply of
lipids.
Certain fibric acid derivatives (clofibrate and bezafibrate)
are effective in lowering plasma lipid levels, although the
exact mechanism of action remains unclear (Fallon et al.,
1972). One mechanism suggests an increased rate of
metabolism of triglyceride-rich lipoproteins due to an in-
crease in the activity of lipoprotein lipase by an inhibition of
adenylate cyclase activity (Greene et al., 1970). The resulting
decrease in cyclic AMP would be expected to reduce lipolysis
and increase tissue lipoprotein lipase activity. Such an effect
may modulate lipid uptake by the tumour as well as attenu-
ating the catabolic activity of tumour lipolytic factors which
act by increasing cyclic AMP levels in adipose tissue (Tisdale
& Beck, 1991).
This study determines the effect of bezafibrate on the
growth and lipid metabolism of the MAC16 tumour, which
induces cachexia in recipient animals, as compared with the
effect on the MAC13 tumour, which has a comparable hist-
ology and growth rate, but which has no effect on host lipid
stores in order to investigate the relationship between
mobilisation of lipids in cachexia and growth of the tumour.
Material and methods
Pure strain NMRI mice bred in our own colony were fed a
rat and mouse breeding diet (Pilsbury, Birmingham, UK)
and water ad libitum. Fragments of either the MAC16 or
MAC13 tumour were implanted into the flank of male
NMRI mice (starting weight 24-26 g) by means of a trocar,
as described (Bibby et al., 1987). Animals bearing the
MAC16 tumour develop weight loss 10-12 days following
tumour transplantation and were used when weight loss
averaged 2 g (average tumour weight 200 mg). Animals bear-
ing the MAC13 tumour were used when the tumour volume
was comparable with that in animals bearing the MAC16
tumour. The dimensions of the tumours were measured daily
by the use of calipers. The tumour volume was calculated
from the formula: length x (width)2 divided by two.
Animals bearing either type of tumour were randomised
into groups of five animals which either received bezafibrate
(100 mg kg-') administered daily by i.p. injection in arachis
oil (100 ,Ll), or arachis oil (100 gl) alone. Body weight, food
and water intake, and tumour volume were determined daily
for each group.
To determine the direct effect of bezafibrate on tumour
growth rate, MAC16 cells were grown in vitro in RPMI1640
tissue culture medium containing 10% foetal calf serum
(Gibco Europe, Paisley, Scotland) under an atmosphere of
5% CO2 in air. Bezafibrate dissolved in ethanol was added to
cells at an initial density of 4 x I04ml-', such that the final
concentration of ethanol in the culture medium was 1%.
Control samples contained ethanol alone. Cell number was
enumerated after 72 h continuous incubation with the drug,
using a Coulter electronic particle counter. Experiments were
performed in triplicate.
Tissue lipid accumulation in the presence ofbezafibrate
The accumulation of an oral dose of '4C-lipid was deter-
mined using the method of Oller do Nascimento and
Williamson (1986). 1-'4C-Triolein (50pCikg-') (Amersham
International, Amersham, Bucks, UK) was administered
orally by gastric intubation, without anaesthesia and with
minimal stress to male NMRI mice bearing the MAC16
tumour 3 days after daily administration of bezafibrate
(200 mkg kg-') or arachis oil controls. After 2 h animals were
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anaesthetised and blood was collected by cardiac puncture.
The complete gastrointestinal tract was removed and
homogenised in 5 ml of 3% (w/v) HC104. Lipids were ext-
racted from organs and blood by the method of Stansbie et
al. (1976). The extracted fatty acids were dissolved in
Optiphase scintillation fluid and the radioactivity determined
using a Packard Tri-Carb 2000 CA liquid scintillation
analyser. Triolein absorption was calculated by subtracting
the total gastrointestinal tract radioactivity from that
administered.
Determination oftissue lipoprotein lipase (LPL) activity
Animals were killed 3 days after administration of
bezafibrate (100 mg kg-') or arachis oil control and the heart
and tumour were removed onto ice, homogenised in cold
acetone and extracted with acetone and ether before being
stored at - 200C. LPL activity in the resolubilised powder
was determined using 3H-triolein as substrate using fasted rat
serum as the source of the activator apoprotein C-Il. The
3H-labelled fatty acids released after a 60 min incubation
period were extracted and determined by the method of
Nilsson-Ehle and Schotz (1976). Lipolysis was identified as
LPL activity because it was inhibited by addition of 2 M
NaCl to the assay medium.
animals (0.83 ± 0.03 mM in bezafibrate treated animals com-
pared with 0.73 ± 0.08 mM in arachis oil controls).
In order to investigate the mechanism of increased lipid
intake in bezafibrate treated animals, the effect on lipoprotein
lipase (LPL), the main enzyme involved in removing triacyl-
glycerol from the plasma, was investigated. The results pre-
sented in Table III show a significantly elevated level of LPL
in the heart but not in the tumour of bezafibrate treated
animals. This suggests that bezafibrate stimulates lipid uptake
into the heart by increasing tissue LPL levels, and that
accumulation of lipid in the tumour must occur by some
other mechanism.
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Statistical analysis
All results are expressed as mean ± SEM for at least three
separate determinations. Differences were evaluated statisti-
cally by Student's t-test.
Results
The effect of daily i.p. administration of bezafibrate
(100mg kg-') on the growth rate of the MAC16 tumour in
animals with weight loss (2-4 g) is shown in Figure la.
Tumour growth rate was significantly (P<0.01) enhanced
within 2 days of drug administration and the overall increase
in tumour volume during the 4 day period in bezafibrate
treated animals was three times that of animals administered
solvent alone. There was no difference in the growth rate of
the tumour in the presence and absence of the arachis oil.
The mean food and water intake of animals administered
bezafibrate (3.7 ± 0.7 g and 3.7 ± 0.6 ml mouse'l day- ',
respectively) was not significantly different from solvent alone
(5.1 ± 0.6 g and 4.4 ± 0.4 ml mouse- 1 day-', respectively),
although animals treated with bezafibrate had an increased
rate of weight loss (Figure lb), probably due to the more
rapid growth of the tumour. Previous studies (Beck & Tis-
dale, 1987) have shown a linear correlation between weight
loss and tumour burden. In contrast with the effect on the
growth ofthe MAC16 tumour, growth ofthe MAC13 tumour,
which does not induce cachexia, was not affected by
bezafibrate using the same dose schedule (Figure lc).
Growth of the MAC16 tumour in vitro was unaffected by
corlcentrations of bezafibrate up to 1 mM (Table I). This
suggests that the in vivo growth stimulatory effect must arise
from an indirect action, possibly through the availability of
lipids to the tumour, which are not limiting for growth in
vitro
In order to investigate the effect of bezafibrate on the
ability of the animals to deal with administered lipid 1'4C-
triolein was administered by intragastric intubation 3 days
after the initiation of bezafibrate administration, and the
absorption and tissue accumulation over a 2h period was
compared with solvent treated controls. While the absorption
of the '4C-lipid was not significantly different between the
two groups (94.8 ± 3.8% for bezafibrate treated animals and
95.4 ± 0.5% for arachis oil controls) the pattern of distribu-
tion was different, with a significantly elevated accumulation
in heart, gastrocnemius muscle and tumour in bezafibrate
animals (Table II). This effect occurred without a significant
alteration in plasma FFA levels in bezafibrate treated
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Figure 1 Effect of bezafibrate (100mg kg') (0) or arachis oil
(0) administered daily to male NMRI mice by i.p. injection on
the tumour volume increase, a, or weight loss, b, in animals
bearing the MAC16 tumour or the tumour volume increase of
the MAC13 tumour, c. Animals bearing the MAC16 tumour had
lost 2 to 4 g in weight before the experiment was initiated.
Differences a, P <0.05; b, P <0.01; c, P <0.005; and d,
P<0.001 between control and bezafibrate-treated animals were
evaluated statistically using Student's t-test.
Table I Effect of bezafibrate on the growth of the MAC16 tumour
in vitro
% Of control cell
Bezafibrate gtm Cell number x 10 growth
0 3A5±0.25 100
1 3.10±0.10 89±2
10 3.10±0.11 90±3
100 3.10±0.20 89±5
500 3.10 0.30 89 7
1,000 3.17±0.23 93±6
u
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Table H Effect of bezafibrate on the metabolic fate of orally administered 1-'4C-trioleina
Tissue "C-lipid accumulation
(% absorbed dose 2h-'g-')
Thigh Gastrocnemius
Group Liver Heart Brain Adipose muscle muscle Plasma Tumour
Control 0.70 ± 0.08 0.95 ± 0.10 0.27 ± 0.01 0.81 ± 0.11 0.68 ± 0.03 0.70 ± 0.01 0.21 0.04 0.18 0.02
Bezafibrate 1.02 ± 0.16 1.27± 0.09b 0.29± 0.02 1.09± 0.41 0.73± 0.07 0.83 ± 0.05b 0.15± 0.02 0.26± 0.03b
aAnimals were administered I-_4C-triolein I h after the last injection of bezafibrate. Results are expressed as mean ± SEM
for six animals per group. bp <0.05 from controls by Student's t-test.
Table III Effect of bezafibrate treatment on the activity of LPL in
heart and tumoura
LPL (nmole fatty acid released min- mg tissue-')
Tissue Control Bezafibrate
Tumour 0.20 ± 0.03 0.16 ± 0.04
Heart 1.43 ±0.08 3.75 0.07b
aThe results are mean ± SEM for separate determinations in
duplicate for five animals per group and were measured 4 days after
the initiation of bezafibrate treatment. The experiment was repeated
twice. bP <0.001 from control values by Student's t-test.
Discussion
In addition to playing a structural role in membrane architec-
ture, lipids are also important regulatory metabolites in cell
function. Thus complexes of essential fatty acids such as
linoleic acid with bovine serum albumin have been shown to
stimulate the growth of human breast carcinoma cells in
culture (Rose & Connolly, 1990) and to significantly enhance
the growth of transplantable mammary adenocarcinomas in
mice (Abraham & Hillyard, 1983). Lipoxygenase metabolites
oflinoleic acid may be an important element in the epidermal
growth factor (EGF)-regulated cascade of biochemical events
leading to fibroblast mitogenesis (Glasgow & Eling, 1990),
while phospholipids containing arachidonic and linoleic acids
can inhibit a guanosine triphosphatase (GTPase) activating
protein (GAP) which stimulates the rate at which the 21 kDa
gene product of the Harvey ras proto-oncogene converts
bound GTP to GDP, and thus inactivates p21 (Tsai et al.,
1989). In addition ras proteins must be isoprenylated at a
conserved cysteine residue near the carboxyl terminus in
order to bind to the inner surface of the plasma membrane
and exert their biological activity (Manne et al., 1990).
Thus lipids play an essential role in tumour development
and the loss of body lipids accompanying cancer cachexia
may be an essential prerequisite for. the growth of some
tumours. This suggests that it may be possible to modify
tumour growth rate by the regulation of the supply of lipids
to the tumour. Inhibition of the process of cachexia, with
consequent retention of adipose tissue triglycerides by both a
ketogenic diet (Tisdale et al., 1987) and by the polyun-
saturated fatty acid eicosapentaenoic acid (EPA) (Tisdale &
Beck, 1991) also results in an inhibition of the growth rate of
the MAC16 tumour. In the present study we have shown
that the lipid lowering agent bezafibrate, which increases
peripheral uptake of lipids is also capable of stimulating the
growth of the MAC16 tumour, while having no effect on the
growth of the MAC13 tumour, which does not induce
cachexia in the host. In vitro studies suggest that the
stimulatory effect of bezafibrate on tumour growth is not due
to a direct effect of the drug on cell growth and that it only
occurs in the in vivo situation.
The pattern of stimulation of tumour growth by bezafibrate
closely follows the serum FFA levels in cachectic animals
with maximum stimulation occurring when the animals had
lost between 8 and 16% of body weight which coincided with
the peak level of serum FFA in these animals (Briddon et al.,
1991). However, bezafibrate did not significantly change the
plasma FFA levels in tumour-bearing animals. Bezafibrate
stimulated lipid accumulation into heart and gastrocnemius
muscle in addition to tumour after an oral dose of 1-'4C-
triolein. The increased lipid in the heart most likely arose
from an increased accumulation of plasma 18 triglycerol due
to an increased tissue level of LPL. The level of LPL in
tumour was low and was not increased by bezafibrate. Thus
the increased tumour level probably arose from an increased
uptake of circulatory FFA as previously suggested (Mermier
& Baker, 1974), since fibrate drugs have previously been
shown to stimulate uptake of FFA into Ehrlich ascites cells
in incubation medium containing albumin (Spector &
Soboroff, 1971). The increase in uptake appears to be due to
a weakening of the bonds between the FFA and albumin.
The results are consistent with the hypothesis that certain
tumours in vivo are highly dependent on exogenous lipid for
their growth and that mobilisation of host fat stores are an
essential factor in this process. If the nature of the lipid
product and its role in growth are determined, it may be
possible to directly attack the growth of slow-growing solid
tumours through this pathway.
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